trending Market Intelligence /marketintelligence/en/news-insights/trending/Lx3kJnTc-SGzyqfcM94RDw2 content esgSubNav
In This List

Health Canada approves Pediapharm ear infection drug

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Health Canada approves Pediapharm ear infection drug

Health Canada approved Pediapharm Inc.'s Otixal for the treatment of acute otitis media with tympanostomy tubes in pediatric patients.

Otixal is an antibiotic and steroid combination ear drop.